Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts

Transplantation

Volumn 64, Issue 12, 1997, Pages 1701-1705

  Kovarik, J ^a   Wolf, P ^b   Cisterne, J M ^c   Mourad, G ^d   Lebranchu, Y ^e   Lang, P ^f   Bourbigot, B ^g   Cantarovich, D ^h   Girault, D ⁱ   Gerbeau, C ⁱ   Schmidt, A G ^a   Soulillou, J P ^h  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c CHU RANGUEIL   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e CHU BRETONNEAU   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g SERVICE DE RHUMATOLOGIE   (France)

^h HÔTEL DIEU   (France)

ⁱ NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; STEROID; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; BODY WEIGHT; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG TOLERABILITY; EDEMA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MALE; METABOLIC DISORDER; NUTRITIONAL DISORDER; PRIORITY JOURNAL; URINARY TRACT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; CADAVER; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS;

EID: 0031449076     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199712270-00012     Document Type: Conference Paper

References (10)

1. Soulillou JP, Cantarovich D, LeMauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
2. Kirkman RL, Shapiro ME, Carpenter CB, et al. Randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107.
3. van Gelder T, Zietse R, Mulder AH, et al. Double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administered to prevent acute rejection after kidney transplantation. Transplantation 1995; 60: 248.
4. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.
5. Kovarik JM, Rawlings E, Sweny P, et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996; 28: 913.
6. Consam user's manual for CONSAM, version 30. Seattle, WA: Resource facility for kinetic analysis, 1990.
7. Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker, 1992: 349.
8. Soulillou JP. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 1994; 46: 540.
9. Trang JM. Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In: Ferraiolo BL, ed. Protein pharmacokinetics and metabolism. New York: Plenum Press, 1992: 223.
10. Kupiec-Weglinski JW, Hahn HJ, Kirkman RL, et al. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monocolonal antibody therapy. Transplant Proc 1988; 20(suppl 2): 207.